Cargando…

Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer

Background: It is still controversial to employ osimertinib as the first-line therapy for EGFR-mutated non-small cell lung cancer (NSCLC) patients in practice. The aim of the current study was to explore the risk factors of acquired T790M mutation during EGFR-TKIs therapy, and to identify the potent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ouyang, Wen, Yu, Jing, Huang, Zhao, Chen, Gang, Liu, Yu, Liao, Zhengkai, Zeng, Wei, Zhang, Junhong, Xie, Conghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052924/ https://www.ncbi.nlm.nih.gov/pubmed/32127933 http://dx.doi.org/10.7150/jca.37991

Ejemplares similares

Concomitant T790M mutation and small‐cell lung cancer transformation after acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor
por: Fujita, Kohei, et al.
Publicado: (2016)

Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
por: Ouyang, Wen, et al.
Publicado: (2020)

Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Chai, Chee-Shee, et al.
Publicado: (2020)

Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations
por: Wang, Yuehong, et al.
Publicado: (2016)

Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
por: Zhou, Yongchun, et al.
Publicado: (2018)

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2018)

Epidermal Growth Factor Receptor T790M Mutation Testing in Non-Small Cell Lung Cancer: An International Collaborative Study to Assess Molecular EGFR T790M Testing in Liquid Biopsy
por: Filipits, Martin, et al.
Publicado: (2023)

Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors
por: Ma, Guangzhi, et al.
Publicado: (2017)

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
por: Ricciuti, Biagio, et al.
Publicado: (2017)

Detection of epidermal growth factor receptor T790M mutation by allele-specific loop mediated isothermal amplification
por: Arjuna, Srividya, et al.
Publicado: (2020)

Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation
por: Hanan, Emily J., et al.
Publicado: (2014)

Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status
por: Liao, Jun, et al.
Publicado: (2022)

An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases
por: Tsuchiya, Kazuo, et al.
Publicado: (2018)

Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
por: Wang, Yuli, et al.
Publicado: (2016)

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
por: Saad, Nibal, et al.
Publicado: (2017)

Incidental diagnosis of pulmonary cryptococcosis by rebiopsy for epidermal growth factor receptor T790M mutation: A case report
por: Kobe, Hiroshi, et al.
Publicado: (2022)

Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer
por: Akazawa, Yu, et al.
Publicado: (2020)

T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma
por: Mirtavoos-Mahyari, Hanifeh, et al.
Publicado: (2022)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
por: Watanabe, Kana, et al.
Publicado: (2023)

The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
por: Ma, Guangzhi, et al.
Publicado: (2017)

Molecular dynamics simulation analysis of the effect of T790M mutation on epidermal growth factor receptor protein architecture in non-small cell lung carcinoma
por: Peng, Xiao-Nu, et al.
Publicado: (2017)

Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status
por: Xu, Haiyan, et al.
Publicado: (2021)

Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
por: Lee, Jang Ho, et al.
Publicado: (2023)

De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
por: Fujiwara, Takumi, et al.
Publicado: (2020)

Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Hu, Shanliang, et al.
Publicado: (2022)

FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
por: Odogwu, Lauretta, et al.
Publicado: (2017)

Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation
por: Zhang, Shirong, et al.
Publicado: (2015)

The Epidermal Growth Factor Receptor (EGFR / HER-1) Gatekeeper Mutation T790M Is Present in European Patients with Early Breast Cancer
por: Bemanian, Vahid, et al.
Publicado: (2015)

Pitfalls in diagnosis with the use of circulating tumor‐derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M
por: Ogawara, Daiki, et al.
Publicado: (2017)

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
por: Zou, Bin, et al.
Publicado: (2017)

The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer
por: Pan, Guoqiang, et al.
Publicado: (2021)

Value of postoperative radiotherapy for stage IIIa-N2 non-small cell lung cancer: an analysis based on SEER database
por: Yang, Ran, et al.
Publicado: (2022)

Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial‐mesenchymal transition in a lung adenocarcinoma patient with EGFR‐TKI drug resistance
por: Xu, Song, et al.
Publicado: (2017)

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience
por: Sullivan, Ivana, et al.
Publicado: (2016)

Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation
por: Hayakawa, Daisuke, et al.
Publicado: (2019)

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer
por: Suda, Kenichi, et al.
Publicado: (2015)

Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2023)

Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
por: Pereira, Isabel, et al.
Publicado: (2020)

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer
por: Gou, Lan-Ying, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4s9nonfa7vbspm797fh0a9iin6